Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Shares Outstanding (2022 - 2025)

BioXcel Therapeutics has reported Shares Outstanding over the past 4 years, most recently at $22.3 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $22.3 million for Q4 2025, up 619.79% from a year ago — trailing twelve months through Dec 2025 was $22.3 million (up 619.79% YoY), and the annual figure for FY2025 was $22.3 million, up 619.79%.
  • Shares Outstanding for Q4 2025 was $22.3 million at BioXcel Therapeutics, up from $20.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding for BTAI hit a ceiling of $29.3 million in Q3 2023 and a floor of $1.8 million in Q4 2022.
  • Median Shares Outstanding over the past 4 years was $13.3 million (2025), compared with a mean of $15.0 million.
  • Biggest five-year swings in Shares Outstanding: plummeted 92.78% in 2024 and later skyrocketed 653.43% in 2025.
  • BioXcel Therapeutics' Shares Outstanding stood at $1.8 million in 2022, then grew by 6.37% to $1.9 million in 2023, then surged by 65.79% to $3.1 million in 2024, then skyrocketed by 619.79% to $22.3 million in 2025.
  • The last three reported values for Shares Outstanding were $22.3 million (Q4 2025), $20.0 million (Q3 2025), and $6.6 million (Q2 2025) per Business Quant data.